To investigate the current situation of accessibility of essential medicines for children in China, to provide reference for the establishment of children's essential medicines list and to promote the accessibility of essential medicines for children in China.
By comparing the "Model List of Essential Medicines for Children" issued by WHO in 2021 and the "National Essential Medicines List" issued by China in 2018, the list of essential medicines for children was screened and a questionnaire was made. From March 3 to March 20, 2022, a survey on the accessibility of 124 essential medicines was conducted in 31 children's specialized hospitals and maternal and child health hospitals across the country in the form of questionnaires. The survey included drug availability, manufacturers, prices and usage in 2021.
Among the 124 investigated drugs, 106 drugs were available and 18 drugs were unavailable. Among the available drugs, the average availability of chemical drugs, biological products and proprietary Chinese medicines was 40.51%, 35% and 27.6%, respectively. The median price ratio (MPR) of 12 primary drugs was 7.62, and the MPR of 46 generic drugs was 1.95. The MPR of 11 drugs with both primary and generic drugs were 8.35 and 1.43, respectively. The affordability analysis of 5 essential medicines for children with asthma, nephrotic syndrome and epilepsy showed that the drug cost of 1 treatment plan was lower than the national daily minimum wage, indicating that the affordability of the 5 drugs was well affordable. For the 9 essential medicines with both primary and generic drugs, 5 primary drugs were used more frequently than generic drugs, and the other 4 drugs were used less frequently than generic drugs.
Among the 124 essential medicines, the availability of chemical drugs, biological products and proprietary Chinese medicines was low. For the essential medicines commonly used in children for asthma, epilepsy and nephrotic syndrome, generic drugs have reasonable prices and good affordability. The price of the primary drug is basically reasonable, and the affordability is weaker than that of generic drugs. The frequency of use of the primary drug was slightly higher than that of the generic drug.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |